According to announcements issued by the stock exchanges, effective March 9, Haixi Pharma (HKEX: 2637.HK) has been officially admitted to the Stock Connect list. This achievement attests to the Company’s profound industry accumulation and widespread market recognition in the innovative drug space. Eligible mainland investors may henceforth trade the Company’s H shares listed on The Stock Exchange of Hong Kong Limited directly via the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect.
The Company’s admission to Stock Connect is a strong endorsement from capital markets for its dedicated layout, robust R&D strengths and promising growth potential in innovative pharmaceuticals. It also stands as a major milestone in the expansion of the Company’s capital market presence and will fuel the implementation of its global development strategy. The Company’s admission to Stock Connect is a strong endorsement from capital markets for its dedicated layout, robust R&D strengths and promising growth potential in innovative pharmaceuticals. It also stands as a major milestone in the expansion of the Company’s capital market presence and will fuel the implementation of its global development strategy.
About the Stock Connect Mechanism
Stock Connect is the core of the Mainland-Hong Kong Stock Market Interconnection Scheme, comprising the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect. It has established an efficient channel for two-way capital flows between the Mainland and Hong Kong capital markets, enabling eligible Mainland investors to trade securities listed on The Stock Exchange of Hong Kong Limited conveniently via domestic stock exchanges.
Admission to the Stock Connect eligible list follows a strict selection procedure. Hang Seng Indexes Company conducts comprehensive assessments across key indicators including market capitalization, stock liquidity and regulatory compliance. Revisions to the list of eligible securities constitute the primary criteria for Stock Connect admissions.
Since the official launch of the Shanghai-Hong Kong Stock Connect in 2014, the Mainland-Hong Kong Stock Market Interconnection Scheme has operated steadily for more than ten years. It has evolved into a core channel for Mainland capital to allocate assets in Hong Kong and capture development opportunities in Hong Kong’s capital market.
About Haixi Pharma
Haixi Pharma is a leading domestic enterprise engaged in the research, development and production of innovative pharmaceuticals. The Company has independently established an integrated R&D platform featuring the full workflow of selective multi-target discovery, preclinical optimization and clinical translation. We have made major breakthroughs in multiple R&D projects covering inflammation, immunomodulation and other therapeutic areas. The Company has built a diversified innovative drug pipeline. Its core proprietary innovative drug candidates are progressing steadily toward R&D and commercialization, targeting global first-in-class and China first-in-class status.
